drugset / Trial / NCT01334203

A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)

NCT01334203

Phase 4 Withdrawn Gilead Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy of ranolazine compared to placebo on duration of exercise assessed by exercise tolerance testing (ETT) at anticipated peak ranolazine plasma concentration after 12 weeks of treatment in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM).

Timeline

Start
2011-05
Primary completion
2012-10
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 500 mg Oral
Subject Ranolazine Small molecule 1000 mg Oral